

Gefapixant: Adis Evaluation

Key Points

- A P2X3 receptor antagonist is being developed by Merck & Co. for the treatment of chronic cough
- Received its first approval on 20 January 2022 in Japan
- Approved for use in refractory or unexplained chronic cough

Summary

Gefapixant (Lyfnua®; Merck & Co.) is a first-in-class, non-narcotic, selective P2X3 receptor antagonist being developed for the treatment of refractory chronic cough or unexplained chronic cough.

Marketing approval for gefapixant is being sought in the EU and USA, and the drug was recently approved for marketing in Japan as treatment for refractory or unexplained chronic cough. This article summarizes the milestones in the development of gefapixant leading to this first approval.

This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © Springer Nature Switzerland AG 2022.